

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Samuel Wei Liu Examiner #: 79120 Date: 12-30-2002
Art Unit: 1653 Phone Number 306-3483 Serial Number: 091975923
Mail Box and Bldg/Room Location: 9B01/9D08 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. *ME*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

*Please search cyclic peptide structure of Formula I (claim 1)
(for the limitations, please see the attached copy).*

X = absent

Thanks!

Samuel

Point of Contact:
Susan Hanley
Technical Info. Specialist
CM1 6B05 Tel: 305-4053

STAFF USE ONLY


	Type of Search	Vendors and cost where applicable
Searcher: <u>Hanley</u>	NA Sequence (#) _____	<u>STN</u> _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) <u>1</u>	Questel/Orbit _____
Date Searcher Picked Up: <u>1/2</u>	Bibliographic _____	Dr.Link _____
Date Completed: <u>1/8</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: _____	Other _____	Other (specify) _____

Claims

What is claimed is:

5

1. A cyclosporin analog of formula (I) or a pro-drug or a pharmaceutically acceptable salt thereof:




10

(I)

wherein,

(a) A is of the formula:



15

wherein

(1) X

is absent, -C1-C6 alkyl-, or -C3-C6 cycloalkyl-;

Y

is selected from the group consisting of:

- i. -C(O)-O-R1 where R1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy, halogen substituted C1-C6 alkylthio;
- ii. -C(O)-S-R1 where R1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy, halogen substituted C1-C6 alkylthio;

20

(2) Y = COOCH₃

25

- iii. $-C(O)-OCH_2-OC(O)R_2$ where R_2 is C1-C6 alkyl, optionally substituted with halogen, C1-C6 alkoxy, C1-C6 alkylthio, heterocyclics or aryl;
- iv. $-C(S)-O-R_1$ where R_1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy, halogen substituted C1-C6 alkylthio; and
- v. $C(S)-S-R_1$ where R_1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy, halogen substituted C1-C6 alkylthio.

- (b) B is $-\alpha Abu$, $-Val$, $-Thr$ or $-Nva$; and
- (c) U is $-(D)Ala$, $-(D)Ser$ or $-[O-(2-hydroxyethyl)(D)Ser]$; or $-[O-acyl(D)Ser]$ or $-[O-(2-acyloxyethyl)(D)Ser]$.

2. A cyclosporin analog according to Claim 1 or a pro-drug or a pharmaceutically acceptable salt thereof, wherein in formula (I), B is $-\alpha Abu$, and U is $-(D)Ala$.

3. A cyclosporin analog according to Claim 1 or a pro-drug or a pharmaceutically acceptable salt thereof, wherein in formula I:

(i) A is of the formula A1 or A2, wherein:

X is absent; and

Y is selected from a group consisting of:

- i. $-C(O)-O-R_1$ where R_1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy, halogen substituted C1-C6 alkylthio;
- ii. $-C(O)-S-R_1$ where R_1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy, halogen substituted C1-C6 alkylthio; and

iii. C(O)-OCH₂-OC(O)R₂ where R₂ is C1-C6 alkyl optionally substituted with halogen, C1-C6 alkoxy, C1-C6 alkylthio, heterocyclics or aryl;

- 5 (ii) B is - α Abu-; and
(iii) U is -(D)Ala-.

4. A cyclosporin analog according to claim 1 or a pro-drug or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
- 10 Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -COOCH₃;
Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -COOH;
15 Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -COOEt;
Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -COOCH₂CH₂CH₃;
Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -COOCH₂Ph;
20 Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -COOCH₂F;
Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -COOCHF₂;
25 Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -COOCF₃;
Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -COOCH₂CF₃;
Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -COOCH₂Cl;
30 Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -COOCH₂OCH₃;
Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -COOCH₂OCH₂CH₂OCH₃;
35 Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is absent, Y = -C(=O)SCH₂Ph;
Compound of Formula (I) wherein B = - α Abu-, U = -(D)Ala-, X is -CH₂CH₂CH₂-, Y = -COOCH₃; and

Compound of Formula (I) wherein B = $-\alpha\text{Abu}-$, U = $-(\text{D})\text{Ala}-$, X is absent, Y = $-\text{COOFmoc}$.


5. A chemical process for preparing a cyclosporin analog of formula I as claimed in Claim 1, comprising:
- reacting a compound of formula I, wherein A = $-\text{MeBmt}-$ with:
 - an olefin of formula $\text{CH}_2=\text{CH}-\text{X}-\text{Y}$, wherein X and Y are as defined in Claim 1; and
 - a catalyst;
 - hydrogenating the product of step a in an organic solvent under
and optionally converting the product of said reaction into a pharmaceutically acceptable salt.
6. The chemical process as claimed in Claim 5, wherein the catalyst in step (a) (ii) is Grubb's ruthenium alkylidene, Nolan's catalyst, a benzylidene catalyst or a molybdenum catalyst.
7. The chemical process as claimed in Claim 5, wherein step (b) is performed at room temperature.
8. The chemical process as claimed in Claim 7, wherein the catalyst in step (b) is Palladium on carbon.
9. A pharmaceutical composition, said composition comprising at least one cyclosporin analog of formula 1 as claimed in Claim 1, said cyclosporin analog being present alone or in combination with a pharmaceutically acceptable carrier or excipient.
10. A method for treating diseases characterized by airflow obstruction in a subject in need of treatment which comprises the step of administering to said subject a therapeutically effective amount of at least one cyclosporin analog of formula I as claimed in Claim 1.
11. The method of Claim 10, wherein said disease is asthma.

12. The method of Claim 10, wherein the step of administering the cyclosporin analog of formula I is done by topical administration.


Patent 6,632,600

Abstract

the present invention relates to a cyclosporin analog of the following formula (I) or a pro-drug or pharmaceutically acceptable salt thereof:



In formula I, the formula for residue A is:



where X is absent, -C1-C6 alkyl-, or -C3-C6 cycloalkyl-; Y is selected from the groups: -C(O)-O-R1; -C(O)-S-R1; -C(O)-OCH2-OC(O)R2; -C(S)-O-R1; and -C(S)-S-R1; where R1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio or halogen substituted C1-C6 alkoxy, halogen substituted C1-C6 alkylthio and where R2 is C1-C6 alkyl optionally substituted with halogen, C1-C6 alkoxy, C1-C6 alkylthio heterocyclics or aryl; B is - α Abu-, -Val-, -Thr- or -Nva-; and U is -(D)Ala-, -(D)Ser- or -[O-(2-hydroxyethyl)(D)Ser]-, or -[O-acyl(D)Ser]- or -[O-(2-acyloxyethyl)(D)Ser]-.

15 In a second embodiment, the present invention relates to the use of the cyclosporin analogs of the present invention or a pro-drug or pharmaceutically acceptable salt thereof in pharmaceutical compositions for the treatment of asthma and other diseases characterized by airflow obstruction in a subject. In a third embodiment, the present invention relates to processes for the production of novel
20 cyclosporin analogs of the present invention. The present invention also contemplates method(s) of treatment of asthma and other diseases characterized by airflow obstruction in a subject by administering to the subject therapeutically effective amounts of the cyclosporin analogs of the present invention with or without the concurrent use of other drugs or pharmaceutically acceptable carriers
25 or excipients.

30

① Registry Search


LIU 09/975,923

=> d que 18

L4 (940)SEA FILE=REGISTRY ABB=ON PLU=ON 12606.8.1/RID

L5 STR parent STRUCTURE

10 11
OH Me



← open, anything can attach here

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS E22 C E11 N AT 1

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 8

Hy must be a heteroring w/ 22 c's
& 11 N's - this forces it to be
a cyclosporin ring

STEREO ATTRIBUTES: NONE

L6 (54)SEA FILE=REGISTRY SUB=L4 SSS FUL L5 54 cpds fit L5

L7 STR subset str searched against L6
answer set



↑ isolated alkyl group

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 13

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L8 0 SEA FILE=REGISTRY SUB=L6 SSS FUL L7 * NO COMPOUNDS *
for this specie

② parent search for reg file

LIU 09/975,923

=> d que 13
L1 (940)SEA FILE=REGISTRY ABB=ON PLU=ON 12606.8.1/RID
L2 STR

10 11
OH Me

Hy- C- C- CH2- CH2- CH2
1 2 3 4 5 6

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E22 C E11 N AT 1


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
L3 54 SEA FILE=REGISTRY SUB=L1 SSS FUL L2

=> d scan 13

L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic
acid]-7-[O-(3-carboxy-1-oxopropyl)-L-threonine]- (9CI)
SQL 11
MF C66 H117 N11 O16

RELATED SEQUENCES AVAILABLE WITH SEQLINK





HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):53


L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminononanoic
acid]-7-L-norvaline- (9CI)
SQL 11
MF C64 H117 N11 O12

since there are no hits
for the species, I am
giving you the "d scan"
print out of the 54
cpds from the parent
search in the Regfile
If you want to pursue any
of these - give me a call.

I retrieved the
citations for 2 cpds
that I thought were
close




RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 2-(O-acetyl-D-serine)-6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]-7-L-threonine- (9CI)
 SQL 11
 MF C64 H115 N11 O15

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 2-D-serine-6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]-7-L-norvaline- (9CI)
 SQL 11
 MF C63 H115 N11 O13

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin D, 6-[(2S,3R,4R)-3-hydroxy-4-methyl-2-(methyamino)octanoic
 acid]- (9CI)
 SQL 11
 MF C63 H115 N11 O12


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.


PAGE 1-A

i-Pr

PAGE 1-B



PAGE 1-C




```

L3      54 ANSWERS      REGISTRY  COPYRIGHT 2003 ACS
IN      Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic
        acid]-7-[O-[4-[[ (3',6'-dihydroxy-1-oxospiro[isobenzofuran-1(3H),9'-
        [9H]xanthen]-4'-yl)methyl]amino]-1,4-dioxobutyl]-L-threonine]- (9CI)
SQL     11
MF      C87 H130 N12 O20


```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A




PAGE 1-B



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminononanoic
 acid]-7-L-valine- (9CI)
 SQL 11
 MF C64 H117 N11 O12


RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-8-
 [[(phenylamino)carbonyl]oxy]-L-2-aminooctanoic acid]- (9CI)
 SQL 11
 MF C69 H118 N12 O14

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A




PAGE 1-B

— NHPH


L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 2-D-threonine-6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-
 aminooctanoic acid]- (9CI)
 SQL 11
 MF C63 H115 N11 O13

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin C, 6-[(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)octanoic acid]- (9CI)
 SQL 11
 MF C62 H113 N11 O13

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]-11-(N-methyl-L-alanine)- (9CI)
 SQL 11
 MF C59 H107 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4,8-trimethyl-L-2-aminononanoic
 acid]- (9CI)
 SQL 11
 MF C64 H117 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N2,4-dimethyl-8-oxo-L-2,8-
 diaminooctanoic acid]- (9CI)
 SQL 11
 MF C62 H112 N12 O13

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 2-(O-acetyl-D-serine)-6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]-7-L-valine- (9CI)
 SQL 11
 MF C65 H117 N11 O14

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)octanoic acid]- (9CI)
 SQL 11
 MF C62 H113 N11 O12
 CI COM


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.


PAGE 1-A

i-Pr


PAGE 1-B



PAGE 1-C




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(R)-3-hydroxy-N,4,4-trimethyl-L-2-aminooctanoic acid]-
 (9CI)
 MF C63 H115 N11 O12



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4,10-trimethyl-L-2-aminoundecanoic
 acid]- (9CI)
 SQL 11
 MF C66 H121 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-8-(benzoyloxy)-3-hydroxy-N,4-dimethyl-L-2-
 aminooctanoic acid]- (9CI)
 SQL 11
 MF C69 H117 N11 O14

RELATED SEQUENCES AVAILABLE WITH SEQLINK



```
L3      54 ANSWERS      REGISTRY  COPYRIGHT 2003 ACS
IN      Cyclosporin A, 2-(O-acetyl-D-serine)-6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-
        aminooctanoic acid]-7-L-norvaline- (9CI)
SQL     11
MF      C65 H117 N11 O14
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK




```
L3      54 ANSWERS      REGISTRY  COPYRIGHT 2003 ACS
IN      Cyclosporin A, 6-[(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-10-oxo-10-
        (propylamino)decanoic acid]- (9CI)
SQL     11
MF      C67 H122 N12 O13
```


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic
 acid]-10-(4-fluoro-L-valine)- (9CI)
 SQL 11
 MF C62 H112 F N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminononanoic
 acid]-7-L-threonine- (9CI)
 SQL 11
 MF C63 H115 N11 O13


RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic
 acid]-7-L-valine-8-(N-methyl-D-norvaline)- (9CI)
 SQL 11

MF C66 H121 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Cyclosporin A, 2-(O-acetyl-D-serine)-6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]- (9CI)

SQL 11

MF C64 H115 N11 O14

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Cyclosporin A, 6-[(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)octanoic acid]-, compd. with 2-methoxy-2-methylpropane (1:2) (9CI)

SQL 11

MF C62 H113 N11 O12 . 2 C5 H12 O

RELATED SEQUENCES AVAILABLE WITH SEQLINK

CM 1


RELATED SEQUENCES AVAILABLE WITH SEQLINK


Absolute stereochemistry.

PAGE 1-A

i-Pr

PAGE 1-B






CM 2

t-Bu-O-Me


L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic
 acid]-7-(4,4-difluoro-L-2-aminobutanoic acid)- (9CI)
 SQL 11
 MF C62 H111 F2 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminodecanoic acid]-
 (9CI)
 SQL 11
 MF C64 H117 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic
 acid]-8-(N-methyl-D-norvaline)- (9CI)
 SQL 11
 MF C65 H119 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminononanedioic
 acid]- (9CI)
 SQL 11
 MF C63 H113 N11 O14


RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic
 acid]-7-L-valine-8-[N-methyl-L-2-(methylthio)glycine]- (9CI)
 SQL 9
 MF C64 H117 N11 O12 S

Absolute stereochemistry.


PAGE 1-A






L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(2S,3R,4R)-3,8-dihydroxy-4-methyl-2-(methylamino)octanoic acid]- (9CI)
 SQL 11
 MF C62 H113 N11 O13

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-7-phenyl-L-2-aminoheptanoic acid]- (9CI)
 SQL 11
 MF C67 H115 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK





L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin D, 6-[(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)octanoic
 acid]-8-[(2R)-N-methyl-2-(methylthio)glycine]- (9CI)
 SQL 11
 MF C64 H117 N11 O12 S

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.


PAGE 1-A






L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 2-D-serine-6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]- (9CI)
 SQL 11
 MF C62 H113 N11 O13

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-8-(acetyloxy)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]- (9CI)
 SQL 11
 MF C64 H115 N11 O14

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 3-(4-hydroxy-N-methyl-L-leucine)-6-[(3R,4R)-3,8-dihydroxy-
 N,4-dimethyl-L-2-aminooctanoic acid]- (9CI)
 SQL 11
 MF C62 H113 N11 O14

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-8-methoxy-N,4-dimethyl-L-2-
 aminooctanoic acid]-7-L-norvaline- (9CI)
 SQL 11
 MF C64 H117 N11 O13

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]-7-L-valine-8-(4,5-didehydro-N-methyl-D-norvaline)- (9CI)
 SQL 11
 MF C66 H119 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 2-[O-(1,1-dimethylethyl)-D-serine]-6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]- (9CI)
 SQL 11
 MF C66 H121 N11 O13

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-8-azido-3-hydroxy-N,4-dimethyl-L-2-amino-octanoic
 acid]- (9CI)
 SQL 11
 MF C62 H112 N14 O12


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.


PAGE 1-A

i-Pr

PAGE 1-B




PAGE 1-C




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic
 acid]-7-(3-oxo-L-2-aminobutanoic acid)- (9CI)
 SQL 11
 MF C62 H111 N11 O13

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-8-methoxy-N,4-dimethyl-L-2-aminooctanoic acid]-7-L-valine- (9CI)
 SQL 11
 MF C64 H117 N11 O13

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]-8-(4,5-didehydro-N-methyl-D-norvaline)- (9CI)
 SQL 11
 MF C65 H117 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 5-(N-methyl-D-valine)-6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]- (9CI)
 SQL 11
 MF C62 H113 N11 O12


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.


PAGE 1-A

i-Pr

PAGE 1-B




PAGE 1-C




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic
 acid]-8-[N-methyl-(R)-2-(methylthio)glycine]- (9CI)
 SQL 11
 MF C63 H115 N11 O12 S

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminononanoic acid]-
 (9CI)
 SQL 11
 MF C63 H115 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-8-methoxy-N,4-dimethyl-L-2-
 aminooctanoic acid]-7-L-threonine- (9CI)
 SQL 11
 MF C63 H115 N11 O14

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 2-D-serine-6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]-7-L-threonine- (9CI)
 SQL 11
 MF C62 H113 N11 O14

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin G, 6-[(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)octanoic acid]- (9CI)
 SQL 11
 MF C63 H115 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(2S,3R,4R)-2-amino-3-hydroxy-N,4-dimethyloctanoic
 acid]-9-(4-hydroxy-N-methyl-L-leucine)- (9CI)
 SQL 11
 MF C62 H113 N11 O13


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N,4-dimethyl-7-phenyl-L-2-aminoheptanoic acid]-7-L-valine- (9CI)
 SQL 11
 MF C68 H117 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 6-[(2S,3R,4R)-3-hydroxy-8-methoxy-4-methyl-2-(methylamino)octanoic acid]- (9CI)
 SQL 11
 MF C63 H115 N11 O13


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.


PAGE 1-A

i-Pr

PAGE 1-B




PAGE 1-C




L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin A, 2-D-serine-6-[(3R,4R)-3-hydroxy-N,4-dimethyl-L-2-aminooctanoic acid]-7-L-valine- (9CI)
 SQL 11
 MF C63 H115 N11 O13

RELATED SEQUENCES AVAILABLE WITH SEQLINK



L3 54 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Cyclosporin B, 6-[(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)octanoic
 acid]- (9CI)
 SQL 11
 MF C61 H111 N11 O12

RELATED SEQUENCES AVAILABLE WITH SEQLINK




ALL ANSWERS HAVE BEEN SCANNED

③ citations for "close" cpds

LIU 09/975,923

=> d que 126

L22	1	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	137500-57-3
L23	1	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	114865-26-8
L24	1	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L22
L25	1	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L23
L26	2	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	(L24 OR L25)



=> d ibib abs hitstr 1

L26 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1991:669869 HCAPLUS

DOCUMENT NUMBER: 115:269869

TITLE: Investigations on the metabolic pathways of cyclosporine: II. Elucidation of the metabolic pathways in vitro by human liver microsomes

AUTHOR(S): Christians, U.; Strohmeyer, S.; Kownatzki, R.; Schiebel, H. M.; Bleck, J.; Kohlhaw, K.; Schottmann, R.; Sewing, K. F.

CORPORATE SOURCE: Inst. Allg. Pharmakol., Med. Hochsch. Hannover, Hannover, Germany

SOURCE: Xenobiotica (1991), 21(9), 1199-210

CODEN: XENOBH; ISSN: 0049-8254

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cyclosporine and its metabolites, isolated from human bile and identified by FAB mass spectrometry and ¹H-NMR spectroscopy, were metabolized by human liver microsomes for the identification of new cyclosporine metabolites. From these data a metabolic pathway for cyclosporine, which includes these new cyclosporine metabolites, has been proposed. The new metabolites were isolated by semipreparative HPLC and their chem. structures were elucidated by FAB mass spectrometry. These isolated metabolites were further metabolized and the products identified by FAB mass spectrometry. Fourteen metabolites, whose structure has not yet been elucidated, were isolated after metab. of structurally identified cyclosporine metabolites, and chem. structures for five of these metabolites were proposed. The structures of the new cyclosporine metabolites were: (i) a N-demethylated, carboxylated deriv. (AM1A4N), (ii) a di-hydroxylated, N-demethylated deriv. (AM14N9), (iii) a hydroxylated and carboxylated deriv. (AM1A9), (iv) a dihydroxylated, cyclized and N-demethylated deriv. (AM1c4N9) and (v) a cyclized and carboxylated (AM1cA) deriv. A proposed cyclosporine metabolic pathway comprises a total of 29 metabolites. It consists of four main branches originating from metabolites AM1, AM1c, AM9, and AM4N.

IT 137500-57-3, Cyclosporin A metabolite 1A9


RL: BIOL (Biological study)

(as cyclosporine metabolite, in liver microsomes of humans)

RN 137500-57-3 HCAPLUS

CN Cyclosporin A, 3-(4-hydroxy-N-methyl-L-leucine)-6-[(3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanedioic acid]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CO₂H

=> d ibib abs hitstr 2

L26 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1988:416575 HCAPLUS

DOCUMENT NUMBER: 109:16575

TITLE: Study of the conformation of cyclosporine in aqueous medium by means of monoclonal antibodies

AUTHOR(S): Quesniaux, Valerie F. J.; Wenger, Roland M.; Schmitter, Doris; Van Regenmortel, Marc H. V.

CORPORATE SOURCE: Lab. Immunochem., Inst. Mol. Cell. Biol., Strasbourg, 67084, Fr.

SOURCE: International Journal of Peptide & Protein Research (1988), 31(2), 173-85

CODEN: IJPPC3; ISSN: 0367-8377

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The three-dimensional structure of the immunosuppressive cyclic peptide cyclosporine (Cs), detd. in crystal by X-ray anal. and in soln. in aprotic solvents by NMR, differs mainly by the orientation of the 7 carbon side chain of residue 1. Because of its poor soly. in water, the conformation of Cs in aq. medium cannot be studied by NMR methods, which require concns. of the substance of the order of milligram/mL, but can be analyzed by immunochem. methods in which concns. in the nanogram/mL range are detected. In the present study, the ability of a series of monoclonal antibodies (McAbs) raised against Cs to recognize different parts of residue 1 of Cs was detd. from the cross-reactivity of different Cs-analogs modified in residue 1. When Cs is dissolved in aq. buffer, the terminal atoms of residue 1 side chain are not available for binding to antibodies recognizing the face of the mol. defined by residues 1, 2, 3, 10, 11, suggesting that the chain is probably folded back under the mol., as obsd. in the crystal structure. Binding of McAbs to Cs was also affected by conformational modifications of the peptide ring that occur in some Cs-analogs. The results illustrate the potential of McAbs for probing the conformation of Cs-derivs. for which no structural data are available.


IT 114865-26-8

RL: PRP (Properties)

(conformation of, monoclonal antibodies recognition of)

RN 114865-26-8 HCAPLUS

CN Cyclosporin A, 6-[(3R,4R)-3-hydroxy-N2,4-dimethyl-8-oxo-L-2,8-diaminooctanoic acid]- (9CI) (CA INDEX NAME)



LIU 09/975,923

(4)

MARPAT SEARCH


LIU 09/975,923

=> d que 121

L14

STR

parent structure



all oxygens have a
connectivity=1, to
make them C=O

← this is the
cyclosporin ring
skeleton

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 34
CONNECT IS E1 RC AT 35
CONNECT IS E1 RC AT 36
CONNECT IS E1 RC AT 37
CONNECT IS E1 RC AT 38
CONNECT IS E1 RC AT 39
CONNECT IS E1 RC AT 40
CONNECT IS E1 RC AT 41
CONNECT IS E1 RC AT 42
CONNECT IS E1 RC AT 43
CONNECT IS E1 RC AT 44
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:

MLEVEL IS ATOM ON RING NODES AND RING GROUPS
MLEVEL IS CLASS ON CHAIN NODES AND CHAIN GROUPS
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L16

50 SEA FILE=MARPAT SSS FUL L14 (MODIFIED ATTRIBUTES)


L19

STR

subset STR that was searched against
L16 parent set

parent STR gives
50 citations

cyclosporin ring



unsubstituted alkyl

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 6
CONNECT IS E1 RC AT 13
DEFAULT MLEVEL IS ATOM
GGCAT IS LIN AT 6
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E22 C E11 N AT 1

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:

MLEVEL IS ATOM ON RING NODES AND RING GROUPS

MLEVEL IS CLASS ON CHAIN NODES AND CHAIN GROUPS

ECLEVEL IS LIM ON ALL NODES

L21

2 SEA FILE=MARPAT SUB=L16 SSS FUL L19 (MODIFIED ATTRIBUTES) 2 citations

- both are
Applicant's
stuff

=> d ibib abs fqhit 1

L21 ANSWER 1 OF 2 MARPAT COPYRIGHT 2003 ACS





ACCESSION NUMBER: 137:226601 MARPAT
 TITLE: Cyclosporins for the treatment of respiratory diseases
 INVENTOR(S): Or, Yat Sun; Lazarova, Tsvetelina; Hamann, Blake
 Christopher
 PATENT ASSIGNEE(S): Enanta Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069902	A2	20020912	WO 2002-US6541	20020305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002142946	A1	20021003	US 2001-800856	20010305


PRIORITY APPLN. INFO.: US 2001-800856 20010305

AB Novel semisynthetic cyclosporin analogs contg. different amino acids are
 synthesized for use as pharmaceuticals. The compds. can be used for th
 treatment of asthma, allergic rhinitis, bronchitis, etc. Thus,
 cyclosporin analogs were prepd. and their immunosuppressant activity was
 detd. by using the inhibition of the phosphate activity as the parameter.

MSTR 1



G2 = 65



G3 = O
 G4 = alkyl<(1-6)> (SO (1-) G5)
 MPL: claim 1
 NTE: or pharmaceutically acceptable salts
 STE: 25-D

LIU 09/975,923

=> d ibib abs fqhit 2

L21 ANSWER 2 OF 2 MARPAT COPYRIGHT 2003 ACS

ACCESSION NUMBER: 111:127017 MARPAT

TITLE: Fluorescence polarization immunoassay for cyclosporin A and metabolites based on novel cyclosporin A derivatives

INVENTOR(S): Wang, Nai Yi; Wang, Philip P.; Morrison, Marjorie Anne

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: Eur. Pat. Appl., 17 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 283801	A2	19880928	EP 1988-103397	19880304
EP 283801	A3	19900530		
R: BE, CH, DE, ES, FR, GB, IT, LI				
JP 63258491	A2	19881025	JP 1988-73057	19880325
US 5239057	A	19930824	US 1991-776890	19911015
US 5427960	A	19950627	US 1994-318570	19941005
PRIORITY APPLN. INFO.:			US 1987-31494	19870327
			US 1989-376244	19890706
			US 1991-776890	19911015
			US 1993-60598	19930512


GI




AB A method is described for prepn. of cyclosporin A derivs. I [k = 0-1 (k = 0 only if n = 1); m = 0-2; n, p = 0-1; R1 = H or a protecting group; R2 = H, lower alkyl, or CH(OH)Me; W = 1-20 (not including H) atoms of C, N, O, S, with .ltoreq.2 heteroatoms bonded together and with O never bonded to O or S; X = CH2, CHOH, C(O) (n = 0), or CH2OH (p = 0); Y = O, S, or NH; Z = a poly(amino acid), a poly(amino acid) deriv., a fluorescent moiety, OH, NH2, NHH2, ORa, SRa, NHRa, NRRa (Ra, Rb = stable C1-10 chain), SH, or a leaving group; MeVal, MeLeu, Sar, and Abu represent residues of N-methylvaline, N-methyllleucine, sarcosine, and L-.alpha.-aminobutyric acid, resp.]. The derivs. are used as (1) immunogens in formation of antibodies specific to cyclosporin A and some metabolites, and (2) precursors in synthesis of fluorescent tracers having .gtoreq.1 epitope in common with cyclosporin A and some metabolites. Antibodies and tracers

are employed in a fluorescence polarization immunoassay (FPIA) for cyclosporin A and metabolites in biol. fluids. [6-(Carboxymethyloximino)-3-(R)-hydroxy-4-(R)-methyl-2-(S)-methylaminohexanoyl]6cyclosporin A (I; k = 0; m, n, p = 1; R1, R2 = H; W = NOCH2; Y = O; Z = OH) (prepn. given) was conjugated to bovine serum albumin with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-HCl, and the resulting immunogen was used to immunize exptl. animals. A fluorescent cyclosporin A tracer was prepd. from [7-carboxy-3-(R)-hydroxy-4-(R)-methyl-2-(S)-methylamino-6-heptenoyl]6cyclosporin A (I; k = 0; m, n, p = 1; R2 = H; W = CH; Y = O; Z = OH) and aminomethylfluorescein-HCl. To serum or plasma samples was added pptn. reagent (30 mM NH4OAc in 98.5% aq. Me2CHOH). Following mixing and centrifuging, samples were analyzed with an automated assay employing an Abbott TDx Analyzer and a Cyclosporin and Metabolites Reagent pack. FPIA sensitivity was 15 ng/mL for cyclosporin A and metabolites. In a comparison of 208 clin. samples against an available RIA, linear regression anal. gave a slope of 1.153, an intercept of 21.06, and a correlation coeff. of 0.813.

MSTR 1B



G1 = OH
G6 = 64-56 67-58



G8 = CH
G10 = O
G11 = 73

G12-Ak
73 74

G12 = O
GGA = 74 76 <(1-10)>
MPL: claim 3
NTE: substitution is restricted
STE: 2-D